129 results about "Uricacidemia" patented technology

The invention discloses a lactobacillus buchneri complex microbial inoculant and application thereof, and belongs to the technical field of microorganisms. In order to solve the problem of poor direct degradation effect of lactic acid bacteria on uric acid in the prior art, the invention provides a complex microbial inoculant containing lactobacillus buchneri NEFU-1 and NEFU-2, and the complex microbial inoculant has the functions of degrading uric acid, relieving hyperuricemia, degrading inosine and / or guanosine, improving intestinal flora composition and reducing inflammatory factors; the lactobacillus plantarum has important significance on preventing, improving and treating gout and hyperuricemia diseases, has high application value and can be applied to preparation of fermented yoghurt.

The invention relates to an application of a sugarcane polyphenol extract in preparation of a medicine for preventing and / or treating hyperuricemia. The invention also discloses application of the sugarcane polyphenol extract in medicines or health care products for gout caused by hyperuricemia, chronic gout, liver injury and kidney injury. The technical problem to be solved is how to provide the sugarcane polyphenol extract, the sugarcane polyphenol extract contains at least 32 polyphenol monomers, the uric acid reducing effect is improved through the synergistic effect among the polyphenol monomers, and the sugarcane polyphenol extract can be used for preparing drugs or health care products for preventing and / or treating hyperuricemia.

The invention discloses a preparation method and application of a medicinal and edible traditional Chinese medicine compound with an effect of treating uric acid diseases. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 15 to 25 parts of semen plantaginis, 15 to 25 parts of pawpaw, 5 to 15 parts of rhizoma smilacis glabrae, 5 to 15 parts of herba portulacae, 1 to 11 parts of radix glycyrrhizae preparata, 5 to 15 parts of folium mori, 5 to 15 parts of folium perillae, 1 to 11 parts of semen pruni, 5 to 15 parts of rhizoma polygonati, 1 to 11 parts of black dates and 1 to 9 parts of mulberries. The traditional Chinese medicine compound is composed of medicinal and edible raw materials, has stable efficacy of reducing uric acid and relieving uric acid liver and kidney injury, renal fibrosis and gouty arthritis, can relieve arthrocele caused by gout, reduces the level of joint inflammatory factors and the like, and takes effect quickly. The traditional Chinese medicine composition can be used for treating hyperuricemia, uric acid nephropathy, gouty arthritis and hyperuricemia accompanying symptoms.

Disclosed in the present invention is an siRNA for inhibiting the expression of a urate transporter 1 (URAT1) gene in human cells. In the present invention, a plurality of siRNAs capable of inhibiting URAT1 expression are obtained by screening, and on this basis, appropriate modifications are performed to obtain sequences with improved target silencing ability. Drugs with the siRNAs as active ingredients are expected to be clinically applicable in the prevention and treatment of diseases related to the URAT1 target, such as gout, hyperuricemia, gouty arthritis and renal calculi.

The invention discloses a marine fish uric acid lowering peptide with kidney protection activity as well as a preparation method and application of the marine fish uric acid lowering peptide. The marine fish uric acid reducing peptide Trp-Gly-Val-Pro-Glu, WGVPE for short, with kidney protection activity is prepared, and the marine fish uric acid reducing peptide Trp-Gly-Val-Pro-Glu, WGVPE for short, can remarkably reduce the blood uric acid level in a body, promote uric acid excretion and improve pathological damage of the kidney. In addition, the pentapeptide provided by the invention can be used in common food, food additives and functional food for preventing and treating hyperuricemia and kidney injury or health care products or medicines for relieving hyperuricemia and kidney injury, and has a good application prospect.

The present invention belongs to the field of traditional Chinese medicine technology, specifically relating to a traditional Chinese medicine composition and its use for preventing or treating hyperuricemia. The technical problem to be solved by the present invention is to provide a new option for treating hyperuricemia. The technical solution of the present invention is a traditional Chinese medicine composition for preventing or treating hyperuricemia, comprising the following ingredients: thistle, gardenia, bamboo leaves, angelica, lily, corn silk, broccoli seed extract, and eucommia leaves. The traditional Chinese medicine composition of the present invention has the effects of inhibiting uric acid synthesis, promoting uric acid excretion, improving kidney damage, and protecting the liver.

The invention belongs to the technical field of biological medicine, and relates to application of a clerodendranthus spicatus tea bag in regulating intestinal excretion and reducing uric acid. One of the purposes of the invention is to provide the application of the clerodendranthus spicatus teabag in regulating intestinal tracts to reduce uric acid According to a preferred embodiment, the clerodendranthus spicatus teabag regulates ATP binding cassette transporter G2 and inhibits uricase activity. The invention provides the application of the clerodendranthus spicatus teabag in regulating the intestinal microbial environment and reducing uric acid, and the clerodendranthus spicatus teabag has remarkable beneficial effects. The clerodendranthus spicatus teabag can effectively regulate the structure and the function of intestinal microflora, especially the enrichment amount of characteristic bacteria Muriaculum in the intestinal tract, further strengthens the probiotic activity of the intestinal flora, and is helpful for maintaining the steady state of uric acid in the body. The multi-way synergistic effect not only provides an innovative strategy for preventing and treating hyperuricemia and related metabolic diseases, but also avoids side effects possibly brought by traditional medicines, and shows good application prospects and clinical values.

The invention belongs to the field of biological medicine, and particularly relates to application of urolithin D in preparation of medicine for relieving hyperuricemia. It is found for the first time that the urolithin D can significantly reduce the level of serum uric acid, improve the expression disorder of a kidney urate transporter, efficiently relieve or treat hyperuricemia and related diseases thereof, and relieve kidney injury and fibrosis; and the compound can be used for preparing medicines for treating hyperuricemia and related diseases, is low in cost and good in safety, and has a wide application prospect.

A food medicine for reducing blood uric acid and treating gout is characterized in that celery seeds, celery, mulberry fruits, mulberry leaves, sea buckthorn fruit powder, dandelions, rhizoma polygonati, poria cocos and beach kidney grass serve as a basic formula; the auxiliary materials comprise one, several or all of a plurality of formula combinations of ramulus mori, lycium ruthenicum, radix puerariae, Chinese yam, clerodendranthus spicatus, lysimachia christinae hance, acanthopanax, anserine, astragalus membranaceus, purslane, herba cepbalanoplosis segeti, galangal, hovenia dulcis thunb, astragalus membranaceus, luteolin, uric acid-reducing edible probiotics and the like, and are used for treating hyperuricemia and gout.

The invention relates to the technical field of traditional Chinese medicines, and discloses application of an active ingredient of shiny-leaved yellowhorn leaves in preparation of a medicine for treating hyperuricemia. The xanthoceras sorbifolia leaf active ingredients comprise quercitrin, rutin and myricetin; the content of quercitrin is 0.2508 mg / g to 0.6719 mg / g, the content of rutin is 0.6707 mg / g to 1.5831 mg / g, and the content of myricetin is 0.8002 mg / g to 3.4858 mg / g. According to the invention, myricetin, quercitrin and rutin are determined as core effective substances of shiny-leaved yellowhorn leaves for treating hyperuricemia for the first time; the multi-target and multi-channel action mechanism is disclosed; meanwhile, network pharmacological analysis shows that the three components have high connectivity in a network and jointly act on key targets such as XOD, ACE, AKR1B1 and TNF, it is prompted that the three components do not act singly, but play a treatment role through multi-target and multi-channel cooperation, the traditional'single target-single drug 'thinking is changed into a'multi-component-multi-target-multi-channel' system regulation mode, and the treatment effect is improved. A new thought is provided for comprehensive treatment of the hyperuricemia.

The present invention provides a pharmaceutical composition comprising a therapeutically effective amount of allopurinol, febuxostat, or a pharmaceutically acceptable salt thereof as an active ingredient for preventing or treating cardiovascular disease, in which the composition is administered to a subject having a serum uric acid level of 6 mg / dl or higher to reduce the serum uric acid level of the subject to less than 6 mg / dl. Therefore, the pharmaceutical composition according to the present invention exhibits an excellent effect on xanthine oxidase inhibitor and is administered to selected subjects to effectively treat or prevent cardiovascular disease.

The invention belongs to the field of medical chemistry, and relates to a benzopyrone compound, a benzopyrone composition and application of the benzopyrone compound and the benzopyrone composition in preparation of a medicine for treating hyperuricemia. The chemical structure is as shown in formula I; in the formula, R1 is fluorine or hydrogen; r2 is fluorine or hydrogen; r3 is hydrogen, nitryl or tertiary butyl; r4 is hydrogen, fluorine or trifluoromethyl; and R1, R2, R3 and R4 are not hydrogen at the same time. The benzopyrone compound provided by the invention has good inhibitory activity on XOD, and can reduce the level of uric acid, thereby being beneficial to treatment of hyperuricemia.

The present invention belongs to the technical field of traditional Chinese medicine, and specifically relates to a traditional Chinese medicine composition for treating hyperuricemia, renal damage and fibrosis, and its application. The technical problem to be solved by the present invention is to provide a new option for the treatment of hyperuricemia. The technical solution of the present invention is a traditional Chinese medicine composition for treating hyperuricemia, renal damage and fibrosis, comprising the following ingredients: mistletoe, phellodendron, oriental water chestnut, ginseng, astragalus, polygonatum, lotus leaf, cirsium japonicum and panax notoginseng. The traditional Chinese medicine composition of the present invention has the effects of inhibiting uric acid synthesis, promoting uric acid excretion, and improving renal damage, and can be used to treat hyperuricemia without causing liver damage.

The invention relates to application of puerarin peptide in preparation of anti-inflammatory and / or uric acid-reducing drugs, and relates to the technical field of drugs. The preparation method of the kudzuvine root peptide comprises the following steps: taking kudzuvine root, extracting to obtain soluble protein, dialyzing to obtain dialyzed protein, performing enzymolysis to obtain crude polypeptide, and purifying to obtain the kudzuvine root peptide. The puerarin peptide is high in purity and strong in activity, can remarkably inhibit inflammatory reaction, reduce the level of inflammatory factors and effectively relieve inflammatory symptoms, and provides a new efficient natural medicine choice for treatment of inflammatory diseases; meanwhile, the pharmaceutical composition can effectively reduce the serum uric acid level of a hyperuricemia animal model, regulate uric acid transport related gene expression to promote uric acid excretion and improve renal functions and histopathologic injury, shows a good uric acid reducing effect, is high in safety and free of obvious toxic and side effects, and is expected to become an innovative medicine for treating hyperuricemia and gout.

This invention discloses an early screening system and method for hyperuricemia based on fingertip blood uric acid detection. The system includes a fingertip blood collection module, a detection module, a data processing module, a storage module, an analysis module, an early warning module, a display module, a communication module, a calibration module, and a power supply module. It accurately collects fingertip blood samples from subjects, obtains blood uric acid concentration data using specific detection equipment, constructs a multi-dimensional analysis model based on clinical characteristic parameters, and determines the optimal diagnostic cutoff value based on ROC curves, achieving rapid and accurate screening for hyperuricemia. The method includes steps such as sample collection, detection, data processing, model analysis, result determination, and early warning. It is simple to operate, fast, and highly accurate, solving the problems of poor compliance and difficulty in grassroots implementation associated with traditional venous blood testing. It is suitable for large-scale population screening and early diagnosis of hyperuricemia in areas with scarce medical resources, and has significant clinical application value and social significance.

This invention belongs to the field of traditional Chinese medicine technology, specifically relating to a traditional Chinese medicine composition, its preparation method, and its uses. By mass parts, the raw materials of the traditional Chinese medicine composition include: 20-60 parts of Acorus calamus, 30-50 parts of Citrus aurantium, 20-60 parts of Benzoin, and 40-100 parts of Catechu. The traditional Chinese medicine composition of this invention has simple and natural components, and clear efficacy. It can effectively reduce the levels of XOD, SUA, CRE, BUN, TNF-α, IL-6, D-Lac, and DAO in the serum of a mouse model of gout, and significantly reduce the renal index, demonstrating good efficacy in treating hyperuricemia and / or gout.

The invention relates to the technical field of medicines, in particular to application of benzbromarone in preparation of antithrombotic drugs. The research finds that benzbromarone clinically used for treating hyperuricemia can be combined with HSP47 on platelets to inhibit the interaction between the HSP47 and collagen so as to reduce platelet activation and thrombosis, which prompts that benzbromarone is an HSP47 inhibitor with an anti-platelet effect; benzbromarone has the effects of inhibiting mouse common carotid artery thrombosis and relieving cerebral ischemia reperfusion injury. Experiments finally confirm that benzbromarone can inhibit formation of common carotid artery thrombosis, does not affect the blood coagulation function, is low in cytotoxicity, has the drug effect similar to that of aspirin and clopidogrel which are commonly used at present, and can become an effective and safe therapeutic drug for cerebral arterial thrombosis.

The invention discloses an application of parabacteroides dieldrii in preparation of a product for treating hyperuricemia. The activity of xanthine oxidase is inhibited through the parabacteroides dieldrii, uric acid related transporters are changed, and damaged organs are protected to play a uric acid reducing effect, so that chronic hyperuricemia is improved. In vitro, the parabacteroides dieldrii can inhibit the activity of xanthine oxidase. On the animal level, the parabacteroides dielsii can relieve liver and kidney injuries caused by hyperuricemia and can repair the injured intestinal barrier at the same time. Therefore, a design thought can be provided for an intestinal flora uric acid reducing preparation, so that a new intestinal flora target is provided for clinical treatment of hyperuricemia. According to the present invention, the activity of xanthine oxidase is inhibited in vitro, the uric acid transporter URAT1 in the kidney is reduced in vivo, the uric acid excretion transporter ABCG2 is increased, and the liver and kidney injury and the intestinal barrier damage caused by hyperuricemia are relieved so as to reduce the serum uric acid level and improve the hyperuricemia;

The invention discloses a uricase mutant. The uricase sequence from aspergillus flavus and the uricase sequence from candida are taken as templates, multiple rounds of random mutation are carried out, sequencing verifies that the key amino acid site of the catalytic center is mutated, and the catalytic activity is enhanced. In-vivo and in-vitro uric acid reducing activities of the two uricase mutants are further verified, and the two uricase mutants can significantly reduce the content of uric acid and are expected to become new uricase drugs for treating hyperuricemia.

The invention belongs to the field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating hyperuricemia and a preparation method and application thereof. The traditional Chinese medicine composition comprises the following main active ingredients in parts by mass: 15-25 parts of fried coix seeds, 15-25 parts of rhizoma smilacis glabrae, 15-25 parts of rhizoma alismatis, 5-15 parts of rhizoma atractylodis, 10-15 parts of semen plantaginis, 10-20 parts of yam rhizome, 10-20 parts of dogwood, 10-20 parts of Chinese yam, 10-20 parts of prepared rehmannia roots, 6-12 parts of prepared radix aconiti lateralis praeparata, 10-15 parts of cassia twigs and 6-12 parts of honey-fried licorice roots. The curative effect and safety evaluation research shows that the uric acid reducing effect of the traditional Chinese medicine composition after 12 weeks of treatment is equivalent to that of febuxostat, compared with febuxostat, the traditional Chinese medicine composition can remarkably reduce the occurrence rate of melt crystal pain of a patient during treatment, the liver and kidney functions of the treated patient are not obviously changed, and the safety is good. Research results show that the traditional Chinese medicine composition is remarkable in clinical curative effect and good in safety.

The invention discloses an application of an NRF2 signal channel activator in preparation of a medicine for preventing or treating hyperuricemia-related atherosclerosis, relates to the technical field of medicines, and particularly relates to an application of the NRF2 signal channel activator in preparation of a medicine for preventing or treating hyperuricemia-related atherosclerosis. The NRF2 signal channel activator is used for up-regulating NRF2 protein expression or enhancing transcriptional activity of the NRF2 protein; the NRF2 signal channel activator is used for up-regulating expression of a downstream target gene SLC7A11 and / or GPX4 so as to inhibit ferroptosis of hyperuricemia aortic macrophages; the level of glutathione (GSH) in serum is increased; the malondialdehyde (MDA) and / or iron ion (Fe < 2 + >) level in serum is reduced; nRF2 signal channel activation and macrophage ferroptosis inhibition are associated, and the NRF2 signal channel is applied to prevention and treatment medicines for hyperuricemia-related atherosclerosis, so that development of specific treatment medicines for patients suffering from hyperuricemia-related atherosclerosis is facilitated.

This invention discloses *Pediococcus lactis* TC-4, which simultaneously degrades nucleosides, purines, and uric acid, and its applications. *Pediococcus lactis* ( Pediococcus acidilactici This invention relates to *Pediococcus lactis* TC-4, with accession number GDMCC No: 67936. *Pediococcus lactis* TC-4 of this invention can efficiently degrade three nucleosides (guanosine, adenosine, and inosine), three purines (guanine, xanthine, and hypoxanthine), and uric acid in vitro. *Pediococcus lactis* TC-4 of this invention can effectively reduce serum uric acid levels in broiler chickens, alleviating and treating hyperuricemia. Compared with traditional chemical drugs for treating hyperuricemia and / or gout, this invention has no toxic side effects on the ecological environment, no residue risk, and is green and safe. This invention has been confirmed at multiple levels, including genetic and animal studies, to have no potential harm to humans, demonstrating its advantages of safety and high efficiency.

The application provides an animal Bifidobacterium lactis HNU329 with the ability of reducing uric acid and an application thereof, the animal Bifidobacterium lactis HNU329 has been preserved in the Guangdong Microbial Culture Collection Center (GDMCC), the preservation address is the 5th floor of the 59th building of the courtyard, No. 100, Jiefang Road, Guangzhou, the preservation date is April 22, 2024, the preservation number is GDMCC No: 64546, and the classification and naming are Bifidobacterium animalis subsp. Lactis. The strain has good degradation abilities of nucleosides and purines in vitro, also shows good uric acid reducing ability and anti-inflammatory ability in animal model evaluation, and can regulate the intestinal flora of hyperuricemia mice and improve the symptoms of hyperuricemia. The strain is non-toxic and has no side effects, is safe, and has a wide application prospect.

The invention discloses a long-chain Dohernia sp. Capable of being colonized in an intestinal anaerobic environment and application of the long-chain Dohernia sp., and relates to the technical field of microorganisms. The invention provides a bacterial strain with a uric acid degradation function, namely the long-chain polyresorcina GH002, the long-chain polyresorcina GH002 has the effects of reducing the uric acid level and preventing and treating hyperuricemia and gout, and the long-chain polyresorcina GH002 also has a certain effect of relieving renal injury. And a novel probiotic or medicine material is provided for treatment of hyperuricemia and related diseases thereof. In addition, eating of the strain has no obvious influence on indexes of a sample body, and it is proved that the strain has the characteristic of high safety and can be widely applied to the fields of medicine and food.

The invention discloses a fermented chicory composition with xanthine oxidase inhibitory activity as well as a preparation method and application of the fermented chicory composition. The composition is prepared by taking chicory roots as a single plant raw material and fermenting the chicory roots with a composite flora consisting of lactobacillus plantarum, lactobacillus rhamnosus, bifidobacterium adolescentis and streptococcus thermophilus in a viable count ratio of 1: 1: 1: 1. The preparation method comprises the steps of culture medium preparation, inoculated fermentation and post-treatment. Through the synergistic fermentation effect of the specific flora and the chicory substrate, the xanthine oxidase inhibitory activity of the product is remarkably enhanced. Metabonomics analysis shows that various active ingredients such as phenolic acids and prebiotic oligosaccharides are remarkably enriched after fermentation, and a dual-action mechanism of directly inhibiting enzyme activity and indirectly regulating intestinal flora is formed. The composition is safe in raw materials and definite in effect, and can be used for preparing medicines, health-care foods or dietary supplements for prevention or adjuvant treatment of hyperuricemia, gout and related diseases.

The application belongs to the technical field of biology and relates to a human uric acid oxidase mutant with weakened immunogenicity and high activity. The human uric acid oxidase mutant with weakened immunogenicity and high activity is obtained by mutating an inactive human uric acid oxidase with an amino acid sequence of SEQ ID NO. 1, and has amino acid substitutions at positions 83, 85, 119, 121, 151, 222, 232, 233, 240 and 252. The human uric acid oxidase mutant has high homology with a theoretical amino acid sequence of human uric acid oxidase, has high activity while reducing immunogenicity, is suitable for long-term application in clinical treatment of hyperuricemia and gout, and can be used for preparing a drug for treating hyperuricemia and gout.

The invention relates to the technical field of hyperuricemia, in particular to lactobacillus reuteri and application thereof in reducing uric acid. The bacterial strain is lactobacillus reuteri WP503 of which the preservation number is CGMCC (China General Microbiological Culture Collection Center) NO.34900, and the bacterial strain is a lactobacillus reuteri WP503 of which the preservation number is CGMCC NO.34900. The bacterial strain has an inhibition effect on metabolic enzymes in a uric acid synthesis route, and especially has an inhibition effect on adenosine deaminase (ADA, EC 3.5. 4.4) and xanthine oxidase (XOD, EC 1.17. 3.2). The strain inhibits uric acid synthesis and reduces the content of serum urate by inhibiting metabolic enzymes of the two uric acid synthesis pathways, and has application prospects in preparation of uric acid reducing preparations.

The invention discloses an application and a preparation method of a marine fish protein peptide with effects of reducing uric acid and protecting kidneys. The marine fish protein peptide VK with uric acid reduction and kidney protection activity is prepared, and the marine fish protein peptide VK can remarkably reduce the blood uric acid level in the body and improve pathological injury of the kidney. Furthermore, the preparation process is further optimized, and the content of the dipeptide VK in the zymolyte is increased. The preparation method provided by the invention is simple in process, realizes enzymolysis controlled release of the target polypeptide, and can be used in common food, food additives and functional food for preventing and treating hyperuricemia and kidney injury or health care products or medicines for relieving hyperuricemia and kidney injury.

The application discloses a metabolic marker, a screening method and application related to gout combined with uric acid nephrolithiasis, and belongs to the technical field of biology. The application analyzes the significant differences of metabolic small molecules in the serum of asymptomatic hyperuricemia and gout combined with uric acid nephrolithiasis patients through a metabolomics method, screens metabolic markers that can be used for predicting gout combined with uric acid nephrolithiasis, and further verifies the sensitivity, specificity and accuracy of the metabolic markers. These findings not only provide markers for early diagnosis and precise treatment of gout combined with uric acid nephrolithiasis, but also provide important basis for understanding the clinical heterogeneity of hyperuricemia and the evolution mechanism thereof.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for activating blood, removing dampness and reducing uric acid and a preparation method and application thereof. The active ingredient of the traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 3-10 parts of prepared radix aconiti lateralis preparata, 5-15 parts of rhizoma zingiberis, 5-15 parts of honey-fried licorice root, 5-15 parts of wine-processed radix cyathulae, 10-30 parts of radix salviae miltiorrhizae, 30-60 parts of rhizoma smilacis glabrae, 10-30 parts of plantain herb and 5-15 parts of radix platycodonis. The traditional Chinese medicine has the effects of tonifying deficiency, dispelling excess, promoting blood circulation, removing dampness, reducing uric acid and strengthening the body resistance, not only strengthens healthy qi to treat root causes, but also promotes blood circulation, removes dampness to treat symptoms, and achieves the effect of treating both symptoms and root causes. Clinical research shows that the traditional Chinese medicine composition disclosed by the invention can be used for reducing the level of uric acid in fasting serum of a patient with hyperuricemia by promoting blood circulation, removing dampness and supporting healthy qi, so that the purpose of effectively treating hyperuricemia is achieved.